Pulmonx Corporation (LUNG) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System.
Analysis Summary
Pulmonx Corporation reported revenue of $90.5M in the most recent fiscal year, growing at a 5-year CAGR of 22.6%.
Trailing-twelve-month margins: gross margin 77.1%, operating margin -53.0%, net margin -55.0%.
At the current price of $2.07, LUNG has negative trailing earnings (P/E not meaningful) and an ROE of -96.66%. Market capitalisation stands at $87M.
Balance sheet quality for LUNG: current ratio of 5.1, net cash position of $13.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $2.07 |
| Market Cap | $87M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.28 |
| EV / EBITDA | -2.18 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -96.66% |
| Return on Invested Capital | -48.39% |
| Return on Assets | -41.94% |
| Gross Margin | 77.06% |
| Operating Margin | -52.96% |
| Net Margin | -55.03% |
Financial Health
| Debt / Equity | 1.43 |
| Current Ratio | 4.32 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LUNG | Pulmonx Corporation | $87M | 2.28 | -96.7% | |
| ABT | Abbott Laboratories | $177.5B | 33.03 | 3.50 | 10.5% |
| 0Y6X.L | Medtronic Plc | $124.2B | |||
| MDT | Medtronic plc | $117.9B | 22.29 | 2.32 | 10.6% |
| SYK | Stryker Corporation | $105.5B | 27.82 | 4.33 | 16.4% |
| 0R2S.L | Stryker Corporation | $103.6B | 28.10 | 4.37 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $64.5B | 47.43 | 5.68 | 11.9% |
| BSX | Boston Scientific Corporation | $64.4B | 17.49 | 2.57 | 14.9% |
Price Performance
| 1 month | -13.91% |
| 3 months | +54.69% |
| Year-to-date | -10.41% |
| 1 year | +17.16% |
| 3 years | -81.23% |
| 5 years | -94.69% |
52-Week Range
| 52-week High | $2.89 |
| 52-week Low | $1.13 |
| Avg Volume (90d) | 517K |
Related companies: ACRV · ASRT · EDAP · HYPR · IMUX · PMVP · RLMD
Explore sector: Healthcare · Medical - Devices
More sections of LUNG: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks